News Scotland to fund BMS skin cancer combo Patient evidence convinces SMC Opdivo+Yervoy is cost-effective.
News UK blood cancer patients get early access to BMS drug Nivolumab made available ahead of EU approval in relapsed cHL.
News BMS' Opdivo still streets ahead of Merck rival BMS to refocus operations, according to Q3 results.
News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News Some good news for BMS with Opdivo + natural killer cell com... But BMS dumps combination with Yervoy.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
